Abstract. Salvianolic acid A (Sal A) is an effective compound extracted from Salvia miltiorrhiza which has been used in the treatment of various diseases. Preliminary data indicate that Sal A treatment has a specific anti-lung cancer effect. However, the manner in which Sal A regulates cancer growth remains unknown. In this study, the A549 lung cancer cell line and its response to Sal A treatment was examined. Results showed that Sal A treatment significantly decreased A549 cell growth, promoted partial apoptosis and increased mitochondrial membrane permeability. Western blot analysis showed that Sal A upregulated the phosphatase and tensin homolog (PTEN) protein level, while consistently downregulating Akt phosphorylation. These results indicate that Sal A negatively mediates A549 lung cancer cell line growth or apoptosis, most likely by positively regulating PTEN protein level.
Introduction
Salvia miltiorrhizae has been used effectively as medicine in China for treatment against various diseases (1) . Besides other compounds with clinical significance purified from Salvia miltiorrhizae, salvianolic acid A (Sal A), one of the soluble components has demonstrated various physiological characteristics including anti-cruor, anti-platelet aggregation and anticancer (2) . Its molecular formula is shown in Fig. 1 . The combination of Sal A and other drugs, such as 5-Fluorouracil, Mitomycin C and Methotrexate, results in the inhibition of cancer growth (3) . Preliminary data have indicated that Sal A is able to inhibit cancer growth in mouse models, including liver, breast and lung cancers. The mechanism of action of Sal A in the regulation of cancer cell growth has yet to be elucidated.
Phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is essential in the regulation of cell survival, growth, differentiation, apoptosis and autophagy (4) . Activation of PI3K phosphorylates phosphatidylinositol (4,5)-bisphosphate (PIP2) by converting it into phosphatidylinositol (3,4,5)-triphosphate (PIP3), thereby preventing cell apoptosis or autophagy. Akt, a key kinase downstream of PI3K in the signaling pathway, is involved in regulating cell status (5) . There are three homologies of Akt in mammalian cells. Of those, Akt1 is pathologically expressed in human cancer cells, suggesting its direct involvement in cancer onset or development (6) . Multiple causes of oncogenic transformation are involved in the regulation of Akt activity (7, 8) . The enhanced Akt activity and the downstream signaling strength result in the Akt-dependent suppression of apoptosis and differentiation, but increase the cell cycle progression (9) .
Phosphatase and tensin homolog (PTEN) deleted on chromosome 10, acts as a phosphatase to dephosphorylate its substrates, causing tumor suppressor (10) . This phosphatase is involved in the regulation of the cell cycle by inhibiting cell growth and division. PTEN as a lipid phosphatase is localized on the membrane (11) . In the cytoplasm, PTEN inhibited PI3K signaling by transforming PIP3 into PIP2 (12) . Due to the lack of PTEN in cytoplasm, PIP3 was accumulated, both Akts and phosphoinositide-dependent kinase-1 (PDK1) contain a PH domain that binds to membrane-bound PIP3. Once in the membrane, PDK1 and mammalian target of rapamycin 1 (mTOR1) activate Akt through phosphorylation at various sites. Thus, the activated Akt positively regulated cell growth or activity, but negatively regulated cell autophagy and apoptosis (13) . PTEN has been demonstrated to be the essential molecule regulating PI3K/AKT pathways and consequently various cell destinations (14) .
In this study, the A549 lung cancer cell line and its response to Sal A treatment was examined. Results showed that Sal A inhibits growth of the A549 lung cancer cell line, induces the trend of apoptosis and at the molecular level, regulates PI3K/ AKT signaling pathway by positively mediating PTEN protein stability. A doses of 20 µl MTT (5 mg/ml) were added to each well prior to reaction for 4 h. The supernatant was removed, the pellet was resuspended and 150 µl dimethyl sulfoxide (DMSO) were added to each well, followed by agitation at room temperature for 15 min to dissolve the precipitates. The absorbance (A) value was measured at 490 nm. The inhibition ratio was calculated as: the inhibition ratio of cell growth = (1-value A of each sample/value A of control) x 100%.
Materials and methods

Cell
Flow cytometry analysis. A549 cells were transferred to a 6-well plate with 2x10 5 /ml and cultured at 37˚C, with 5% CO 2 for 24 h, followed by Sal A treatment at the concentrations of 10, 30 and 60 µg/ml, respectively. The control group was free of the treatment. After 12 h of culturing, cells were stripped with 0.25% trypsin and collected by centrifugation (1000 rpm) at 4˚C for 5 min. The pellets were washed again with cold phosphate-buffered saline (PBS), following the addition of 500 µl binding buffer for cell suspension. The pellets were then mixed with 5 µl Annexin V-FITC and 5 µl propidium iodide for 10 min in the dark and flow cytometer was employed to determine the apoptosis ratio.
Measurement of A549 permeability during Sal A treatment.
After 24-h Sal A treatment A549 cells were washed three times with PBS and mixed with 0.1 µM MitoTracker ® and 10 nM Hoechst for staining. After 30-min reaction at 37˚C, the mixture was washed with PBS three more times, and fixed with 4%-paraformaldehyde for 15 min. Lysates were incubated for 20 min on ice and centrifuged at 12000 x g for 15 min. The supernatant was collected, and the protein concentration was determined by Lowry protein assay. The protein was electrophoresed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 50 g/l non-fat dried milk in PBST (PBS, 0.5 ml/l Tween-20) for 2 h at room temperature and incubated overnight at 4˚C with the first antibody against human PTEN, caspase-3 and a phosphorylated antibody against AKT (first antibodies were purchased from Bioworlde, St. Louis Park, MN, USA), followed by incubation with an HRP-conjugated secondary antibody (Bioworlde) at room temperature for 1 h. Enhanced chemiluminescence (ECL) was used to detect the results.
Results
Sal A had a negative effect on A549 cell growth. The A549 lung cancer cell line was used as a model system to examine the effect of Sal A on its growth. A549 cells were treated with Sal A at various concentrations of 0.01, 0.1, 1, 10 and 100 µg/ml, respectively. At various time points after treatment, cells were counted and the results showed that cell growth decreased at the concentration of ≥10 µg/ml (Table I) . With the increase of Sal A concentration, cell growth was significantly retarded. At 100 µg/ml, the inhibitory ratio of cell growth was ~90%. At 12 h treatment, cells became abnormal and floated.
At 48 h, cell death ratio was the highest. However, at 72 h, cells demonstrated continued growth. This suggested that the growth-inhibitory effect of Sal A was concentration-and time-dependent in the A549 lung cancer cell line.
Sal A induced A549 cell apoptosis. There are multiple locations for treated cells following cell growth inhibition. For instance, cells may undergo autophagy, apoptosis, cell silence or even cell differentiation. To determine the biological consequence of Sal A treatment on A549 cells, flow cytometry was used to examine the cell phases during Sal A treatment. The results showed that cell growth was mostly blocked at G1 phase (data not shown). In addition, at low concentration (10 µg/ml), >16% cells underwent apoptosis (including apoptosis at the earlyand late-stages). With the addition of Sal A the apoptotic rate increased. At high concentrations (30 µg/ml), the apoptotic rate was only 6%, however, most cells were floating and Table I . A549 growth decreased under Sal A treatment. dead ( Figs. 2A and B) , suggesting that apoptosis is one of the dose-dependent consequences of the Sal A-treated A549.
Concentrations Inhibitory ----------------------------------------------------------------------------------------
Sal A increased mitochondrial membrane permeability and the cleaved caspase-3 protein level. To better understand whether or not the induced apoptosis is mitochondrial-dependent, Thermo Cellomics ® ArrayScan ® VTi was applied to examine the membrane permeability of A549 cells during Sal A treatment (Fig. 3A) . In the control group treated with MitoTracker ® staining, the cell membrane exhibited a bright red color. Following the addition of Sal A, the bright red color became weak, indicating that Sal A promoted mitochondrial membrane permeability. Furthermore, at the molecular level, Sal A consistently increased the cleaved caspase-3 protein level (Fig. 3B) . At 24-h treatment, cells were stained with MitoTracker ® staining, as the control: the cell membrane exhibited bright red color (red arrow), at 20 µg/ml, the bright red color was weak and at 30 µg/ml, it almost disappeared. (A) Cells became more condensed. (B) Proteins of A549 treated with the same condition as in Fig. 2 . Western blot analysis was used to detect the cleaved caspase-3 protein level. The concentrations 24, 12 and 6Z indicate medium dose (20 µg/ml) at 24, 12 and 6 h, respectively. C, Control; 12D, 12Z and 12G are representative of low (10 µg/ml), medium (20 µg/ml) and high concentrations (30 µg/ml), respectively.
A B
Sal A upregulated the PTEN protein level and consistently downregulated PI3K/Akt/mTOR signaling pathways. To understand the molecular role of Sal A in regulating A549 cell apoptosis, we examined the PI3K/Akt signaling pathway, which is crucial in regulating cell growth, differentiation and apoptosis. By detecting protein levels using western blot analysis, we found that with Sal A treatment, Akt S473 phosphorylation was downregulated at various time points and Sal A concentrations (Fig. 4) . When examining the potential upstream regulation of Akt, we found that the PTEN protein level was upregulated in the same treatment. These results are consistent with cell apoptosis. In addition, to examine whether or not the regulation of PTEN protein level arose from the gene transcription or the protein stability, gene chips and qPCR were performed to examine the PTEN mRNA level (data not shown). The results suggested that at the mRNA level, no significant difference was detected, even at high concentrations of Sal A treatment, indicating that Sal A might positively regulate PTEN protein level through increasing its stability.
Discussion
Salvia miltiorrhiza is a medical herb that has been used in China as medicine for the treatment of patients with various diseases. Recently, several effective compounds of Salvia miltiorrhiza have been identified as key ingredients in clinical treatments. To the best of our knowledge, our results have demonstrated, for the first time, that Sal A induces apoptosis in human lung cancer cells. Sal A is a hydrophilic molecule and as yet, it is unknown whether its effect is intra-or extracellular. The results of this study demonstrate that this acidic substance has the ability to reduce the viability of lung cancer cells and induce partial apoptosis. The apoptotic rate varied depending on the concentration of Sal A treatment. The medium concentration of Sal A (20 µg/ml) treatment induced a significantly high apoptotic rate. However, at a high concentration of Sal A, cell growth was significantly decreased even though the apoptotic rate was only 6%, suggesting that apoptosis was only one of the consequences of A549 cells responding to Sal A treatment and various cell locations were likely to be interactive.
To further examine the molecular mechanism of Sal A action, we studied the regulation of PI3K/Akt signaling pathway. At the molecular level, the results of repeated experiments suggested that Sal A treatment significantly increased PTEN protein level and consistently decreased phosphorylation of Akt at S473. PTEN expression is reduced in various tumor types, such as lung and breast cancers (15, 16) . The regulation of PTEN protein level is highly involved in the cell growth. The manner in which the PTEN protein level was upregulated following Sal A treatment remains unknown. Our gene chips and real time PCR did not show any difference of PTEN mRNA level at various time points and Sal A concentrations (data not shown). This observation suggests that Sal A might directly regulate PTEN protein stability, and thus the negative regulation of AKT phosphorylation. However, the manner in which PTEN was modified and its stability regulated has yet to be elucidated. Although apoptosis was only partially regulated, the consequence of Sal A treatment and the positive regulation of PTEN stability in response to Sal A are highly correlated with A549 apoptosis. 
